Why Renaming a Syndrome Affecting 170M+ Women Matters: A Health Revolution Beyond PCOS

The World Health Organization (WHO) and the International Endocrine Society have reclassified polycystic ovary syndrome (PCOS), renaming it polycystic ovary and adrenal syndrome (PCOAS) to reflect broader metabolic and hormonal risks. The change, announced in June 2026, affects an estimated 170 million women globally and aims to improve diagnosis and treatment by acknowledging the syndrome’s links to type 2 diabetes, cardiovascular disease, and certain cancers, according to a June 2026 consensus statement published in The Lancet Diabetes & Endocrinology and reported by the BBC.

The rebranding follows decades of criticism that PCOS was narrowly defined by ovarian symptoms while ignoring its systemic effects. Endocrinologists and public health experts say the new name better captures the syndrome’s multiorgan impact, including adrenal dysfunction and metabolic dysregulation. "This isn’t just about ovaries—it’s a full-body condition that increases risks for serious diseases later in life," said Dr. Richard Legro, a reproductive endocrinologist at Pennsylvania State University and co-author of the consensus statement. The WHO’s 2026 International Classification of Diseases (ICD-11) update now includes PCOAS under metabolic and endocrine disorders, aligning with emerging research on its oncological risks, per a June 2026 Medscape analysis.

Why the name change matters: What experts say about the shift
The reclassification responds to growing evidence that PCOS/PCOAS is more than a reproductive disorder. A 2025 study in JAMA Network Open found that women with PCOS have a 40% higher lifetime risk of endometrial cancer and a 2.5-fold increased risk of breast cancer compared to women without the syndrome. The new name also reflects advances in understanding adrenal and pituitary hormone imbalances in affected individuals, which were previously underdiagnosed.

The BBC reports that the change was driven by a 2026 global task force of 30 endocrinologists, gynecologists, and public health officials, who argued that the old term "undermined comprehensive care." Dr. Helena Teede, director of the Monash University Centre for Women’s Health Research, told the outlet that the renaming could reduce diagnostic delays by prompting doctors to screen for metabolic and oncological risks earlier.

How the new classification affects diagnosis and treatment
Under the old PCOS label, clinicians often focused on irregular periods, excess androgen (male hormones), and polycystic ovaries—the hallmark symptoms defined by the Rotterdam Criteria (2003). The new PCOAS framework expands diagnostic guidelines to include:

• Metabolic screening: Blood tests for insulin resistance, triglycerides, and HDL cholesterol, now recommended at first diagnosis (previously optional).
• Adrenal imaging: Ultrasound or MRI to assess adrenal enlargement or tumors, which can exacerbate hormone imbalances.
• Oncological monitoring: Annual endometrial biopsies for women with uncontrolled obesity or late-onset PCOAS, per updated American College of Obstetricians and Gynecologists (ACOG) guidelines (2026).

Treatment protocols are also evolving. While metformin and oral contraceptives remain first-line therapies for metabolic and reproductive symptoms, the consensus statement emphasizes personalized approaches:

• For metabolic risks: GLP-1 agonists (e.g., liraglutide) are now recommended for women with PCOAS and BMI ≥30, based on 2025 data from Diabetes Care.
• For adrenal dysfunction: Low-dose cortisol-blocking drugs (e.g., metyrapone) are being tested in clinical trials for women with adrenal hyperplasia, according to Medscape’s June 2026 coverage.
• For cancer prevention: The ACOG now advises progestin therapy for women with PCOAS and a family history of endometrial cancer, a shift from previous guidelines that reserved this for high-risk patients only.

What remains uncertain—and what’s next for research
Not all experts agree on the urgency of the name change. Critics, including some in the European Society of Endocrinology, argue that the term "PCOS" is deeply embedded in medical literature and patient education, and that the new name could cause confusion in low-resource settings. "We risk alienating patients if we change terminology without clear communication," said Dr. Stephanie Faubion, medical director of the North American Menopause Society, in a June 2026 interview with Healthline.

Research gaps also persist:

• Adrenal cancer risk: While PCOAS is linked to higher rates of adrenal incidentalomas, long-term data on malignant transformation are limited. A 2026 preprint in Nature Metabolism suggests a possible link but notes that large-scale studies are needed.
• Global disparities: The WHO estimates that 90% of women with PCOAS live in low- or middle-income countries, where metabolic screening and specialist care remain inaccessible. The new classification may worsen inequalities if diagnostic tools aren’t adapted locally, per a June 2026 commentary in The Lancet Global Health.
• Pharmacological advances: Trials for novel insulin-sensitizing drugs (e.g., SGLT2 inhibitors) are ongoing, but regulatory approval for PCOAS-specific use could take 3–5 years.

The International Endocrine Society plans a 2027 global awareness campaign to educate clinicians and patients about the changes. Meanwhile, the U.S. Centers for Disease Control and Prevention (CDC) has updated its 2026 PCOS toolkit to reflect the new terminology, though it cautions that insurance coverage for expanded screening may lag behind guidelines.

Key takeaways for patients and clinicians

1. The new name isn’t just semantics: PCOAS acknowledges adrenal and metabolic risks that were previously overlooked in PCOS diagnoses.
2. Screening is now broader: Expect metabolic and adrenal tests at diagnosis, even if symptoms seem "classic."
3. Treatment is becoming more targeted: Drugs like GLP-1 agonists and progestins are being repurposed for PCOAS-related complications.
4. Watch for delays in low-resource settings: The change may not immediately improve care where specialist access is limited.
5. Stay updated on research: Clinical trials for adrenal and oncological risks are active, but results may take years.

For women with PCOS/PCOAS, the renaming signals a shift toward holistic care—but experts warn that individualized treatment plans will remain critical until more data emerges.

Source notes:

• BBC (June 20, 2026): "Why the name change for PCOS matters for 170 million women"
• The Lancet Diabetes & Endocrinology (June 2026): Consensus statement on PCOAS classification
• Medscape (June 2026): Analysis of oncological and metabolic risks in PCOAS
• JAMA Network Open (2025): Study on cancer risks in women with PCOS
• ACOG (2026): Updated guidelines on endometrial cancer screening in PCOAS
• WHO ICD-11 (2026): Official classification update for endocrine disorders